Author

Hideki Nakamura

Institution: Nippon Chemiphar (Japan)

Observed institutions: Nippon Chemiphar (Japan), KM Biologics (Japan)

ORCID: 0009-0006-2817-1217

Observed ORCID: 0009-0006-2817-1217

OpenAlex ID: A5049825122

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind, placebo-controlled, phase 1/2 clinical study in Japan

2022 · Mitsuyoshi Tanishima, Kayo Ibaraki, et al. · medRxiv · 5

Design and Synthesis of Pyrazolomorphinan Derivatives as Novel Delta Opioid Receptor Agonists

2025 · Hideaki Fujii, Chiharu Iwamatsu, et al. · Journal of Medicinal Chemistry · 2

Potassium/Sodium Citrate Attenuates Paclitaxel-Induced Peripheral Neuropathy

2025 · Daisuke Uta, Hideki Nakamura, et al. · International Journal of Molecular Sciences · 2

Preliminary report: Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult participants: a non-randomized, open-label phase 2/3 clinical study in Japan

2022 · Keishi Kido, Kayo Ibaragi, et al. · medRxiv

Works count: 4

Citation count: 9

H-index: 2

I10-index: